PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis

PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis

PARP inhibitors (PARPi), alone or in combination with androgen receptor signaling inhibitors (ARSi), have shown clinical benefit in metastatic castration-resistant prostate cancer (mCRPC), particularly in tumors with homologous recombination repair (HRR) gene alterations. Recent data from the TALAPR...

Full description

Saved in:
Bibliographic Details
Main Authors: Ray Manneh, Javier Molina-Cerrillo, Guillermo de Velasco, Linda Ibatá, Susan Martínez, Álvaro Ruiz-Granados, Teresa Alonso-Gordoa
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Pharmaceuticals
Subjects:
metastatic castration-resistant prostate cancer
PARP inhibitors
DNA repair alterations
precision oncology
Online Access:https://www.mdpi.com/1424-8247/18/7/1015
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/18/7/1015

Similar Items